Product nameAnti-Eph receptor B2 antibody
See all Eph receptor B2 primary antibodies
DescriptionRabbit polyclonal to Eph receptor B2
Tested applicationsSuitable for: ICC/IF, IHC-P, ELISA, WBmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide conjugated to KLH, corresponding to amino acids 118-133 of Human Eph B2.
- Mouse heart tissue lysate.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Concentration information loading...
PurityProtein G purified
Purification notesThis antibody is purified through a protein G column and eluted out with both high and low pH buffers and neutralized immediately after elution then followed by dialysis against PBS.
Our Abpromise guarantee covers the use of ab5418 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/100 - 1/500. Detects a band of approximately 116 kDa (predicted molecular weight: 118 kDa).
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionReceptor for members of the ephrin-B family. Phosphorylates ARHGEF15, leading to its ubiquitination and degradation by the proteasome which promotes EFNB1-dependent synapse formation. Can function in aspects of retinal ganglion cell axon guidance to the optic disk even when lacking its tyrosine kinase domain. Acts as a tumor suppressor.
Tissue specificityBrain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain.
Involvement in diseaseDefects in EPHB2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=EPHB2 mutations have been found in a prostate cancer cell line derived from a brain metastasis.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.
Contains 2 fibronectin type-III domains.
Contains 1 protein kinase domain.
Contains 1 SAM (sterile alpha motif) domain.
- Information by UniProt
- cek5 antibody
- Developmentally regulated EPH related tyrosine kinase antibody
- DRT antibody
Anti-Eph receptor B2 antibody (ab5418) at 1/100 dilution + mouse heart tissue lysate at 0.01 µg
Developed using the ECL technique.
Predicted band size: 118 kDa
Observed band size: 118 kDa
Additional bands at: 48 kDa (possible isoform)
ab5418 at a 1/100 dilution staining approximately 116kDa band of Eph B2 in mouse heart tissue lysate by Western blot (ECL).
Human cancer tissue stained with ab5418 followed by peroxidase-conjugated secondary antibody and AEC.
ICC/IF image of ab5418 stained SKNSH cells. The cells were 4% PFA fixed (10mins) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab5418, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Song Y et al. A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer's disease. EBioMedicine N/A:N/A (2018). Read more (PubMed: 30522932) »
- Zhang C et al. Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett 13:2059-2070 (2017). WB . Read more (PubMed: 28454362) »